Ownership
Private
Employees
~10
Stage
Phase 2
Modalities
Mesenchymal stem cell therapyExosome therapyRegenerative medicine

Vitti Labs General Information

FDA approved Phase II IND clinical trial for combination mesenchymal stem cell and exosome treatment of pulmonary fibrosis secondary to COVID-19 infection

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

MSC-exosome combination therapy
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Vitti Labs's pipeline data

Book a demo

Key Partnerships

Academic institutions

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Vitti Labs Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Vitti Labs's complete valuation and funding history, request access »